The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | R | Respiratory system | |
| 2 | R05 | Cough and cold preparations | |
| 3 | R05C | Expectorants, excl. combinations with cough suppressants | |
| 4 | R05CB | Mucolytics | |
| 5 | R05CB02 | Bromhexine |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 24 mg |
| PAREN - Parenteral | 24 mg |
| Active Ingredient | Description | |
|---|---|---|
| Bromhexine |
Bromhexine is an expectorant used in the treatment of respiratory disorders associated with viscid or excessive mucus. Bromhexine is a synthetic derivative of the herbal active ingredient vasicine. It has been shown to increase the proportion of serous bronchial secretion, making it more easily expectorated. It is indicated as “secretolytic therapy in bronchopulmonary diseases associated with abnormal mucus secretion and impaired mucus transport”. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| BISOLVON Oral solution | Health Products Regulatory Authority (IE) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
